Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Retained Earnings (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Retained Earnings for 4 consecutive years, with -$1.5 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 17.52% to -$1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.5 billion through Dec 2025, down 17.52% year-over-year, with the annual reading at -$1.5 billion for FY2025, 17.52% down from the prior year.
  • Retained Earnings for Q4 2025 was -$1.5 billion at Phathom Pharmaceuticals, down from -$1.5 billion in the prior quarter.
  • The five-year high for Retained Earnings was -$570.0 million in Q1 2022, with the low at -$1.5 billion in Q4 2025.
  • Average Retained Earnings over 4 years is -$1.0 billion, with a median of -$970.1 million recorded in 2023.
  • The sharpest move saw Retained Earnings plummeted 39.98% in 2024, then decreased 17.52% in 2025.
  • Over 4 years, Retained Earnings stood at -$727.1 million in 2022, then decreased by 27.73% to -$928.7 million in 2023, then plummeted by 36.0% to -$1.3 billion in 2024, then decreased by 17.52% to -$1.5 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$1.5 billion, -$1.5 billion, and -$1.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.